Faecal calprotectin in differentiating between functional and organic bowel diseases

Arab Journal of Gastroenterology

Volumn 11, Issue 2, 2010, Pages 70-73

  El Badry, Ahmed ^a   Sedrak, Heba ^a   Rashed, Layla ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Faecal calprotectin; Functional bowel disease; Inflammatory bowel disease; Organic bowel disease

Indexed keywords

CALGRANULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL BOWEL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; ORGANIC BOWEL DISEASE; PRIORITY JOURNAL;

EID: 77955266363     PISSN: 16871979     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajg.2010.04.009     Document Type: Article

References (29)

1. Delvaux M. Functional bowel disorders and irritable bowel syndrome in Europe. Aliment Pharmacol Therap 2003, 18(Suppl. 3):75-79.
2. Green P.H., Cellier C. Celiac disease. N Engl J Med 2007, 357(17):1731-1743.
3. Schröder O., Naumann M., Shastri Y., et al. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Therap 2007, 26(7):1035-1042.
4. Costa F., Mumolo M.J., Marchi S., et al. Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests?. World J Gastroenterol 2007, 13(2):219-223.
5. Cronin C.C., Shanahan F. Immunological tests to monitor inflammatory bowel disease - have they delivered yet?. Am J Gastroenterol 1998, 93(3):295-297.
6. Suffredini A.F., Fantuzzi G., Badolato R., et al. New insights into the biology of the acute phase response. J Clin Immunol 1999, 19(4):203-214.
7. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., et al. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. New Engl J Med 2004, 351(26):2704-2714.
8. Sugi K., Saitoh O., Hirata I., et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996, 91(5):927-934.
9. Desai D., Faubion W.A., Sandborn W.J. Biological activity markers in inflammatory bowel disease. Aliment Pharmacol Therap 2007, 25(3):247-255.
10. Limburg P.J., Ahlquist D.A., Sandborn W.J., et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000, 95(10):2831-2837.
11. Tibblea J., Teahon K., Thjodleifsson B., et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000, 47:506-513.
12. Barbara G., Stanghellini V., De Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126(3):693-702.
13. Dale I., Brandtzaeg P., Fagerhol M.K., et al. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol 1985, 84(1):24-34.
14. Andersson K.B., Sletten K., Berntzen H.B., et al. The leucocyte L1 protein: identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1988, 28(2):241-245.
15. Summerton C.B., Longlands M.G., Wiener K., et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002, 14(8):841-845.
16. Hanai H., Takeuchi K., Iida T., et al. Relationship between fecal calprotectin, intestinal inflammation and peripheral blood neutrophils in patients with active ulcerative colitis. Digest Dis Sci 2004, 49(9):1438-1443.
17. Tibble J.A., Sigthorsson G., Bridger S., et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119(1):15-22.
18. Pardi D.S., Sandborn W.J. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?. Gut 2005, 54(3):321-322.
19. Roseth A.G., Schmidt P.N., Fagerhol M.K. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999, 34(1):50-54.
20. Roseth A.G., Fagerhol M.K., Aadland E., et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992, 27(9):793-798.
21. Fagerhol M.K. Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein?. Clin Mol Pathol 1996, 49(2):M74-M79.
22. Johne B., Fagerhol M.K., Lyberg T., et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997, 50(3):113-123.
23. Ton H., Brandsnes Ø., Dale S., et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000, 292(1-2):41-54.
24. El Nuamani N.M., El Gendi H.A., Zaki S., et al. Evaluation of the diagnostic yield of faecal calprotectin in Egyptian children with chronic diarrhea. Arab J Gastroenterol 2007, 8(4):132-135.
25. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130(5):1480-1491.
26. Mayer E.A. Irritable bowel syndrome. New Engl J Med 2008, 358(16):1692-1699.
27. Spiegel B.M., DeRosa V.P., Gralnek I.M., et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004, 126(7):1721-1732.
28. Tomàs A.B., Vidal M.V., Camps A.R. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig 2007, 99(12):689-693.
29. Schoepfer A.M., Trummler M., Seeholzer P., et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP and IBD antibodies. Inflamm Bowel Dis 2008, 14(1):32-39.